Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on March 4, 2015

Conference call scheduled for March 4, 2015 at 8:30 a.m. EST

CAMBRIDGE, Mass.--()--Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report fourth quarter and year ended December 31, 2014 financial results on Wednesday, March 4, 2015. Eleven's management team will host a conference call and audio webcast at 8:30 a.m. EST, on Wednesday, March 4, 2015 to discuss the financial results and recent business developments.

To access the conference call, please dial 844-831-3025 (domestic) or 315-625-6887 (international) at least five minutes prior to the start time and refer to conference ID 87544666. An audio webcast of the call will also be available on the Investors & Media section of the company's website, www.elevenbio.com. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. For more information please refer to the Company’s website www.elevenbio.com.

Contacts

Eleven Biotherapeutics
Leah Monteiro, 617-714-0619
Leah.Monteiro@elevenbio.com

Recent Stories

RSS feed for Eleven Biotherapeutics, Inc.

Website

Release Summary

Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on March 4, 2015

Eleven Biotherapeutics, Inc.